|
1
|
Miller KD, Nogueira L, Mariotto AB,
Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL and Siegel
RL: Cancer treatment and survivorship statistics, 2019. CA Cancer J
Clin. 69:363–385. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brooks RA, Fleming GF, Lastra RR, Lee NK,
Moroney JW, Son CH, Tatebe K and Veneris JL: Current
recommendations and recent progress in endometrial cancer. CA
Cancer J Clin. 69:258–279. 2019.PubMed/NCBI
|
|
4
|
Colombo N, Creutzberg C, Amant F, Bosse T,
González-Martín A, Ledermann J, Marth C, Nout R, Querleu D, Mirza
MR, et al: ESMO-ESGO-ESTRO consensus conference on endometrial
cancer: Diagnosis, treatment and follow-up. Ann Oncol. 27:16–41.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Reijnen C, IntHout J, Massuger LFAG,
Strobbe F, Küsters-Vandevelde HVN, Haldorsen IS, Snijders MPLM and
Pijnenborg JMA: Diagnostic accuracy of clinical biomarkers for
preoperative prediction of lymph node metastasis in endometrial
carcinoma: A systematic review and meta-analysis. Oncologist.
24:e880–e890. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee YC, Lheureux S and Oza AM: Treatment
strategies for endometrial cancer: Current practice and
perspective. Curr Opin Obstet Gynecol. 29:47–58. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tewari KS, Burger RA, Enserro D, Norquist
BM, Swisher EM, Brady MF, Bookman MA, Fleming GF, Huang H, Homesley
HD, et al: Final overall survival of a randomized trial of
bevacizumab for primary treatment of ovarian cancer. J Clin Oncol.
37:2317–2328. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ni J, Kalff-Suske M, Gentz R, Schageman J,
Beato M and Klug J: All human genes of the uteroglobin family are
localized on chromosome 11q12.2 and form a dense cluster. Ann N Y
Acad Sci. 923:25–42. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tassi RA, Calza S, Ravaggi A, Bignotti E,
Odicino FE, Tognon G, Donzelli C, Falchetti M, Rossi E, Todeschini
P, et al: Mammaglobin B is an independent prognostic marker in
epithelial ovarian cancer and its expression is associated with
reduced risk of disease recurrence. BMC Cancer. 9:2532009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Becker RM, Darrow C, Zimonjic DB, Popescu
NC, Watson MA and Fleming TP: Identification of mammaglobin B, a
novel member of the uteroglobin gene family. Genomics. 54:70–78.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wong RL, Wang Q, Treviño LS, Bosland MC,
Chen J, Medvedovic M, Prins GS, Kannan K, Ho SM and Walker CL:
Identification of secretaglobin Scgb2a1 as a target for
developmental reprogramming by BPA in the rat prostate.
Epigenetics. 10:127–134. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ouellette RJ, Richard D and Maicas E:
RT-PCR for mammaglobin genes, MGB1 and MGB2, identifies breast
cancer micrometastases in sentinel lymph nodes. Am J Clin Pathol.
121:637–643. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hassan EM, Willmore WG, McKay BC and
DeRosa MC: In vitro selections of mammaglobin A and mammaglobin B
aptamers for the recognition of circulating breast tumor cells. Sci
Rep. 7:144872017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Aihara T, Fujiwara Y, Miyake Y, Okami J,
Okada Y, Iwao K, Sugita Y, Tomita N, Sakon M, Shiozaki H and Monden
M: Mammaglobin B gene as a novel marker for lymph node
micrometastasis in patients with abdominal cancers. Cancer Lett.
150:79–84. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fiegl M, Haun M, Massoner A, Krugmann J,
Müller-Holzner E, Hack R, Hilbe W, Marth C, Duba HC, Gastl G and
Grünewald K: Combination of cytology, fluorescence in situ
hybridization for aneuploidy, and reverse-transcriptase polymerase
chain reaction for human mammaglobin/mammaglobin B expression
improves diagnosis of malignant effusions. J Clin Oncol.
22:474–483. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Munakata K, Uemura M, Takemasa I, Ozaki M,
Konno M, Nishimura J, Hata T, Mizushima T, Haraguchi N, Noura S, et
al: SCGB2A1 is a novel prognostic marker for colorectal cancer
associated with chemoresistance and radioresistance. Int J Oncol.
44:1521–1528. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bellone S, Tassi R, Betti M, English D,
Cocco E, Gasparrini S, Bortolomai I, Black JD, Todeschini P, Romani
C, et al: Mammaglobin B (SCGB2A1) is a novel tumour antigen highly
differentially expressed in all major histological types of ovarian
cancer: Implications for ovarian cancer immunotherapy. Br J Cancer.
109:462–471. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tassi RA, Bignotti E, Falchetti M, Calza
S, Ravaggi A, Rossi E, Martinelli F, Bandiera E, Pecorelli S,
Santin AD, et al: Mammaglobin B expression in human endometrial
cancer. Int J Gynecol Cancer. 18:1090–1096. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rhodes DR, Kalyana-Sundaram S, Mahavisno
V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ,
Kincead-Beal C, Kulkarni P, et al: Oncomine 3.0: Genes, pathways,
and networks in a collection of 18,000 cancer gene expression
profiles. Neoplasia. 9:166–180. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Boja E, Tezak Z, Zhang B, Wang P, Johanson
E, Hinton D and Rodriguez H: Right data for right patient-a
precisionFDA NCI-CPTAC Multi-omics mislabeling challenge. Nat Med.
24:1301–1302. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and
Varambally S: UALCAN: A portal for facilitating tumor subgroup gene
expression and survival analyses. Neoplasia. 19:649–658. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen F, Chandrashekar DS, Varambally S and
Creighton CJ: Pan-cancer molecular subtypes revealed by
mass-spectrometry-based proteomic characterization of more than 500
human cancers. Nat Commun. 10:56792019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huo Q, Li Z, Cheng L, Yang F and Xie N:
SIRT7 is a prognostic biomarker associated with immune infiltration
in luminal breast cancer. Front Oncol. 10:6212020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang H, Gao S, Chen J and Lou W: UBE2I
promotes metastasis and correlates with poor prognosis in
hepatocellular carcinoma. Cancer Cell Int. 20:2342020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen W, Dai X, Chen Y, Tian F, Zhang Y,
Zhang Q and Lu J: Significance of STAT3 in immune infiltration and
drug response in cancer. Biomolecules. 10:8342020. View Article : Google Scholar
|
|
26
|
Li T, Fan J, Wang B, Traugh N, Chen Q, Liu
JS, Li B and Liu XS: TIMER: A web server for comprehensive analysis
of tumor-infiltrating immune cells. Cancer Res. 77:e108–e110. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tomczak K, Czerwinska P and Wiznerowicz M:
The cancer genome atlas (TCGA): An immeasurable source of
knowledge. Contemp Oncol (Pozn). 19A:A68–A77. 2015.
|
|
28
|
Beroukhim R, Mermel CH, Porter D, Wei G,
Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J,
Urashima M, et al: The landscape of somatic copy-number alteration
across human cancers. Nature. 463:899–905. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mermel CH, Schumacher SE, Hill B, Meyerson
ML, Beroukhim R and Getz G: GISTIC2.0 facilitates sensitive and
confident localization of the targets of focal somatic copy-number
alteration in human cancers. Genome Biol. 12:R412011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sepulveda JL: Using R and Bioconductor in
clinical genomics and transcriptomics. J Mol Diagn. 22:3–20. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mootha VK, Lindgren CM, Eriksson KF,
Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E,
Ridderstråle M, Laurila E, et al: PGC-1alpha-responsive genes
involved in oxidative phosphorylation are coordinately
downregulated in human diabetes. Nat Genet. 34:267–273. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liberzon A, Subramanian A, Pinchback R,
Thorvaldsdóttir H, Tamayo P and Mesirov JP: Molecular signatures
database (MSigDB) 3.0. Bioinformatics. 27:1739–1740. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dellinger TH, Smith DD, Ouyang C, Warden
CD, Williams JC and Han ES: L1CAM is an independent predictor of
poor survival in endometrial cancer-An analysis of the cancer
genome atlas (TCGA). Gynecol Oncol. 141:336–340. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Minaguchi T, Yoshikawa H, Oda K, Ishino T,
Yasugi T, Onda T, Nakagawa S, Matsumoto K, Kawana K and Taketani Y:
PTEN mutation located only outside exons 5, 6, and 7 is an
independent predictor of favorable survival in endometrial
carcinomas. Clin Cancer Res. 7:2636–2642. 2001.PubMed/NCBI
|
|
35
|
Gibson WJ, Hoivik EA, Halle MK,
Taylor-Weiner A, Cherniack AD, Berg A, Holst F, Zack TI, Werner HM,
Staby KM, et al: The genomic landscape and evolution of endometrial
carcinoma progression and abdominopelvic metastasis. Nat Genet.
48:848–855. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Song MS, Salmena L and Pandolfi PP: The
functions and regulation of the PTEN tumour suppressor. Nat Rev Mol
Cell Biol. 13:283–296. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Witek L, Janikowski T, Bodzek P, Olejek A
and Mazurek U: Expression of tumor suppressor genes related to the
cell cycle in endometrial cancer patients. Adv Med Sci. 61:317–324.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen J, Zhao KN, Li R, Shao R and Chen C:
Activation of PI3K/Akt/mTOR pathway and dual inhibitors of PI3K and
mTOR in endometrial cancer. Curr Med Chem. 21:3070–3080. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tu Z, Gui L, Wang J, Li X, Sun P and Wei
L: Tumorigenesis of K-ras mutation in human endometrial carcinoma
via upregulation of estrogen receptor. Gynecol Oncol. 101:274–279.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
McDonald ME and Bender DP: Endometrial
cancer: Obesity, genetics, and targeted agents. Obstet Gynecol Clin
North Am. 46:89–105. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lee II, Maniar K, Lydon JP and Kim JJ: Akt
regulates progesterone receptor B-dependent transcription and
angiogenesis in endometrial cancer cells. Oncogene. 35:5191–5201.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Vassileva V, Millar A, Briollais L,
Chapman W and Bapat B: Genes involved in DNA repair are mutational
targets in endometrial cancers with microsatellite instability.
Cancer Res. 62:4095–4099. 2002.PubMed/NCBI
|
|
43
|
Shweiki D, Itin A, Soffer D and Keshet E:
Vascular endothelial growth factor induced by hypoxia may mediate
hypoxia-initiated angiogenesis. Nature. 359:843–845. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Carmeliet P: VEGF as a key mediator of
angiogenesis in cancer. Oncology. 69 Suppl 3:S4–S10. 2005.
View Article : Google Scholar
|
|
45
|
Hirai M, Nakagawara A, Oosaki T, Hayashi
Y, Hirono M and Yoshihara T: Expression of vascular endothelial
growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal
uterine endometrial carcinoma. Gynecol Oncol. 80:181–188. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Di Cello A, Di Sanzo M, Perrone FM,
Santamaria G, Rania E, Angotti E, Venturella R, Mancuso S, Zullo F,
Cuda G and Costanzo F: DJ-1 is a reliable serum biomarker for
discriminating high-risk endometrial cancer. Tumour Biol.
39:10104283177057462017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Bernstein JL, Godbold JH, Raptis G, Watson
MA, Levinson B, Aaronson SA and Fleming TP: Identification of
mammaglobin as a novel serum marker for breast cancer. Clin Cancer
Res. 11:6528–6535. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Holub K and Biete A: New pre-treatment
eosinophil-related ratios as prognostic biomarkers for survival
outcomes in endometrial cancer. BMC Cancer. 18:12802018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ning C, Xie B, Zhang L, Li C, Shan W, Yang
B, Luo X, Gu C, He Q, Jin H, et al: Infiltrating macrophages induce
ERα expression through an IL17A-mediated epigenetic mechanism to
sensitize endometrial cancer cells to estrogen. Cancer Res.
76:1354–1366. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chang WC, Li CH, Huang SC, Chang DY, Chou
LY and Sheu BC: Clinical significance of regulatory T cells and
CD8+ effector populations in patients with human
endometrial carcinoma. Cancer. 116:5777–5788. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kondratiev S, Sabo E, Yakirevich E, Lavie
O and Resnick MB: Intratumoral CD8+ T lymphocytes as a
prognostic factor of survival in endometrial carcinoma. Clin Cancer
Res. 10:4450–4456. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kelly MG, Francisco AM, Cimic A, Wofford
A, Fitzgerald NC, Yu J and Taylor RN: Type 2 endometrial cancer is
associated with a high density of tumor-associated macrophages in
the stromal compartment. Reprod Sci. 22:948–953. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Jing X, Peng J, Dou Y, Sun J, Ma C, Wang
Q, Zhang L, Luo X, Kong B, Zhang Y, et al: Macrophage ERα promoted
invasion of endometrial cancer cell by mTOR/KIF5B-mediated
epithelial to mesenchymal transition. Immunol Cell Biol.
97:563–576. 2019. View Article : Google Scholar : PubMed/NCBI
|
